C3L-02969
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 76.95550992
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.560
- ALLOGRAFT_REJECTION+0.470
- G2M_CHECKPOINT+0.330
- E2F_TARGETS+0.320
- INFLAMMATORY_RESPONSE+0.320
- APICAL_SURFACE+0.290
- IL6_JAK_STAT3_SIGNALING+0.290
- MTORC1_SIGNALING+0.260
- KRAS_SIGNALING_DN+0.240
Top 10 suppressed
- PROTEIN_SECRETION-0.440
- TGF_BETA_SIGNALING-0.380
- ANGIOGENESIS-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- WNT_BETA_CATENIN_SIGNALING-0.310
- ADIPOGENESIS-0.260
- UV_RESPONSE_DN-0.250
- PEROXISOME-0.230
- DNA_REPAIR-0.210
- ANDROGEN_RESPONSE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613746 | — | D | 0.837 |
| 2 | MNG921 | — | — | 0.826 |
| 3 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.815 |
| 4 | SRR1313144 | — | D | 0.808 |
| 5 | 695836ff-c54b-47bf-8a29-5224811afa7e | — | — | 0.807 |
| 6 | 20030081.TNBC | — | D | 0.805 |
| 7 | C3N-02922 | — | cohortMD2 | 0.803 |
| 8 | BDCM_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.801 |
| 9 | TCGA-34-5232-01A-21R-1820-07 | — | cohortSQ1 | 0.800 |
| 10 | b03d2223-38c1-4bb3-be8b-27db05f87b66 | — | — | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |